Band 3
Provided by Marleen Van den Horst
* IP & technology
* Life sciences, Pharma & regulatory
* Patents and technology
* Healthcare
IP & Technology partner Marleen van den Horst (J.D.) has over 25 years’ experience in multi-jurisdictional patent litigation, since 2023 including cases before the UPC. She successfully represents clients in patent disputes in all fields of technology. She is internationally renowned for her patent, regulatory and product liability work in life sciences. Marleen conducts patent/SPC litigation and advises on blockbuster molecules like escitalopram, glatiramer acetate, rivastigmine, zoledronate, fingolimod, eculizumab and on CRISPRCas9 technology. In the field of high tech/telecoms Marleen advises on European litigation strategy for enforcing SEP patents and FRAND-related issues. She is a frequent speaker at international conferences.
* Board member of the NeoKidney Foundation for the realisation of a wearable artificial kidney.
* Member of several professional organisations and trade associations, such as EPLAW,
AIPPI, LES, VF&R and VIEPA.
Provided by Chambers
Marleen Van den Horst of La Gro is particularly popular with clients from the pharmaceutical industry for advice on the IP aspects of product launches, including patent infringement and invalidity actions. In addition, she represents clients in patent enforcement proceedings.
Provided by Chambers
"Marleen Van den Horst manages to address her client's needs with a very business-oriented mind."
"Marleen Van den Horst manages to address her client's needs with a very business-oriented mind."
Provided by La Gro
Health and Life Sciences
